Quadrant Capital Group’s Enanta Pharmaceuticals ENTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-35
| Closed | -$363 | – | 2754 |
|
|
2024
Q3 | $363 | Hold |
35
| – | – | ﹤0.01% | 2678 |
|
|
2024
Q2 | $454 | Sell |
35
-124
| -78% | -$1.67K | ﹤0.01% | 2635 |
|
|
2024
Q1 | $2.78K | Buy |
159
+124
| +354% | +$1.64K | ﹤0.01% | 2442 |
|
|
2023
Q4 | $330 | Sell |
35
-1,121
| -97% | -$10.4K | ﹤0.01% | 2646 |
|
|
2023
Q3 | $12.9K | Buy |
1,156
+1,074
| +1,310% | +$17.3K | ﹤0.01% | 1891 |
|
|
2023
Q2 | $1.75K | Sell |
82
-287
| -78% | -$8.46K | ﹤0.01% | 2437 |
|
|
2023
Q1 | $14.9K | Sell |
369
-36
| -9% | -$1.72K | ﹤0.01% | 1839 |
|
|
2022
Q4 | $18.8K | Buy |
405
+131
| +48% | +$5.97K | ﹤0.01% | 1688 |
|
|
2022
Q3 | $14K | Buy |
274
+84
| +44% | +$4.91K | ﹤0.01% | 1724 |
|
|
2022
Q2 | $9K | Buy |
190
+12
| +7% | +$651 | ﹤0.01% | 1707 |
|
|
2022
Q1 | $13K | Buy |
178
+14
| +9% | +$911 | ﹤0.01% | 1528 |
|
|
2021
Q4 | $12K | Sell |
164
-26
| -14% | -$2.04K | ﹤0.01% | 1538 |
|
|
2021
Q3 | $11K | Buy |
190
+16
| +9% | +$791 | ﹤0.01% | 1528 |
|
|
2021
Q2 | $8K | Sell |
174
-21
| -11% | -$1.03K | ﹤0.01% | 1664 |
|
|
2021
Q1 | $10K | Buy |
195
+30
| +18% | +$1.5K | ﹤0.01% | 1491 |
|
|
2020
Q4 | $7K | Buy |
165
+90
| +120% | +$3.96K | ﹤0.01% | 1567 |
|
|
2020
Q3 | $3K | Buy |
75
+33
| +79% | +$1.6K | ﹤0.01% | 1701 |
|
|
2020
Q2 | $2K | Sell |
42
-491
| -92% | -$25.4K | ﹤0.01% | 1897 |
|
|
2020
Q1 | $28K | Buy |
533
+491
| +1,169% | +$26.2K | ﹤0.01% | 1140 |
|
|
2019
Q4 | $2K | Hold |
42
| – | – | ﹤0.01% | 2229 |
|
|
2019
Q3 | $2K | Hold |
42
| – | – | ﹤0.01% | 2081 |
|
|
2019
Q2 | $3K | Hold |
42
| – | – | ﹤0.01% | 2064 |
|
|
2019
Q1 | $4K | Hold |
42
| – | – | ﹤0.01% | 1910 |
|
|
2018
Q4 | $2K | Hold |
42
| – | – | ﹤0.01% | 1877 |
|
|
2018
Q3 | $3K | Hold |
42
| – | – | ﹤0.01% | 1708 |
|
|
2018
Q2 | $4K | Hold |
42
| – | – | ﹤0.01% | 1618 |
|
|
2018
Q1 | $3K | Hold |
42
| – | – | ﹤0.01% | 1695 |
|
|
2017
Q4 | $2K | Hold |
42
| – | – | ﹤0.01% | 1764 |
|
|
2017
Q3 | $1K | Hold |
42
| – | – | ﹤0.01% | 1947 |
|
|
2017
Q2 | $0 | Hold |
42
| – | – | ﹤0.01% | 1900 |
|
|
2017
Q1 | $1K | Hold |
42
| – | – | ﹤0.01% | 1780 |
|
|
2016
Q4 | $1K | Hold |
42
| – | – | ﹤0.01% | 1677 |
|
|
2016
Q3 | $1K | Buy |
+42
| New | +$975 | ﹤0.01% | 1656 |
|
|
2016
Q1 | – | Sell |
-25
| Closed | – | – | 1847 |
|
|
2015
Q4 | $0 | Sell |
25
-77
| -75% | -$2.51K | ﹤0.01% | 1604 |
|
|
2015
Q3 | $2K | Hold |
102
| – | – | ﹤0.01% | 951 |
|
|
2015
Q2 | $4K | Buy |
+102
| New | +$3.97K | ﹤0.01% | 865 |
|
Other funds holding ENTA
KAM
FCM
RCM
Quadrant Capital Group's ENTA Position: Q4 2024 in Review
Quadrant Capital Group sold out of Enanta Pharmaceuticals (ENTA) in Q4 2024, closing a stake of 35 shares — an estimated $363 sold.
Quadrant Capital Group first reported a position in ENTA in Q2 2015 and held it in 36 quarters. The position peaked at $28K in Q1 2020. 107 funds tracked by Wall St. Rank hold ENTA as of Q4 2024.
- Quadrant Capital Group reported no remaining Enanta Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
- Quadrant Capital Group sold 35 Enanta Pharmaceuticals shares in Q4 2024, an estimated $363.
- Quadrant Capital Group first reported a position in Enanta Pharmaceuticals in Q2 2015 and held it in 36 quarters.
- Quadrant Capital Group's Enanta Pharmaceuticals position peaked at $28K in Q1 2020.
- 107 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2024.
Based on Quadrant Capital Group's 13F filing for Q4 2024, filed 13 Feb 2025.